CAS: 57645-05-3; (2S)-2-[[2-[1-(4-Chlorobenzoyl)-5-Methoxy-2-Methylindol-3-Yl]Acetyl]Amino]-3-Hydroxypropanoic Acid

上下游产品

吲哚美辛 [1-(4-Chlorobenzoyl)-5-Methoxy-2-Methylindol-3-Yl]Acetic Acid 53-86-1
2-[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基吲哚-3-基]乙酰氯 1-(4-Chlorobenzoyl)-5-Methoxy-2-Methyl-1H-Indole-3-Acetyl Chloride 20357-37-3
(2,5-二氧代吡咯烷-1-基)2-[1-(4-氯苯甲酰基)-5-甲氧基-2-甲基吲哚-3-基]乙酸酯 [1-(4-Chlorobenzoyl)-5-Methoxy-2-Methyl-1H-Indol-3-Yl]Acetic Acid 2,5-Dioxopyrrolidin-1-Yl Ester 104425-42-5

📜吲哚美辛置于sodium Carbonate体系中,用 四氢呋喃,水 作为反应溶剂,化学反应 24.17H,反应生成 丝美辛
参考文献:肽结合作为非分子类抗炎药的超分子凝胶剂:合成,表征和生物学研究.
标题:肽结合作为非分子类抗炎药的超分子凝胶剂:合成,表征和生物学研究.
摘要:消炎痛(ind)是一种众所周知的非甾体类抗炎药(nsaid),与各种天然存在的氨基酸结合在一起.这些生物共轭物中的大多数能够使纯净水,Nacl溶液(0.9 Wt%)和磷酸盐缓冲盐水(ph 7.4)以及一些有机溶剂胶凝.通过台式和动态流变学以及电子显微镜对凝胶进行表征.可变温度1在选定的凝胶上进行1 H NMR光谱研究,以洞悉凝胶形成过程中的自组装过程.在两个胶凝剂的单晶结构中均观测到1D和2D氢键网络.评估了水凝器的合理生物学应用,其最终目的是以自我传递的方式传递药物.所有凝胶化剂在37oc的ph 7.4的磷酸盐缓冲盐水中均稳定,并且在小鼠巨噬细胞raw 264.7细胞系中具有生物相容性(3-(4,5-二甲基噻唑-2-基)-2-,5-二苯基溴化四氮唑测定).生物相容性最强的两种凝胶化剂在前列腺素e 2中显示出与母体药物ind相当的抗炎反应分析.将生物缀合物释放到与相应水凝胶接触的本体溶剂中表明它们在药物递送中可能的未来应用.
DOI:10.1002/asia.201402672

专利信息

专利号:US-2013035307-A1
优先权日:2010-01-26
标 题:Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
发明人：PRESTWICH GLENN D; KENNEDY THOMAS P
权利人:UNIV UTAH RES FOUND; PRESTWICH GLENN D; KENNEDY THOMAS P
摘要:Described herein are methods for the treatment and prevention of tumor metastasis using alkylated and fluoroalkylated semi-synthetic glycosaminoglycan ethers (“SAGEsâ€?). The synthesis of sulfated alkylated and fluoroalkylated SAGEs is also described.

专利号:WO-2023096715-A9
优先权日:2021-10-22
标 题:Immunomodulatory glycosphingolipids and methods of use thereof
发明人：KASPER DENNIS; OH SUNGWHAN
权利人:HARVARD COLLEGE
摘要:Provided herein are a subset of alpha-galactosylceramide (alpha-GC) compounds having improved immunomodulatory activity, particularly with respect to NKT cell number and activity. Also provided herein are methods of use of such compounds, including in the modulation of NKT cells and/or activity in vivo. Further provided are combinatorial synthesis methods for generating alpha-GC compounds of specifically defined structure and thereby generating pure preparations thereof.

专利号:US-2022125838-A1
优先权日:2019-02-11
标题 :Immunomodulatory glycosphingolipids and methods of use thereof
发明人：OH SUNGWHAN; KASPER DENNIS L; SONG HEEBUM; PARK SEUNG BUM
权利人:HARVARD COLLEGE; SEOUL NAT UNIV R&DB FOUNDATION
摘要:Provided herein are a subset of alpha-galactosylceramide (alpha-GC) compounds having improved immunomodulatory activity, particularly with respect to NKT cell number and activity. Also provided herein are methods of use of such compounds, including in the modulation of NKT cells and/or activity in vivo. Further provided are combinatorial synthesis methods for generating alpha-GC compounds of specifically defined structure and thereby generating pure preparations thereof.

专利号:US-9907753-B2
优先权日:2010-03-19
标 题 :Lipid vesicle compositions and methods of use
发明人：IRVINE DARRELL J; MOON JAEHYUN
权利人:MASSACHUSETTS INST TECHNOLOGY
摘要:The invention provides delivery systems comprised of stabilized multilamellar vesicles, as well as compositions, methods of synthesis, and methods of use thereof. The stabilized multilamellar vesicles may comprise prophylactic, therapeutic and/or diagnostic agents.

专利号:US-2023407258-A1
优先权日:2019-09-16
标 题:Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof

专利号:WO-2021055448-A1
优先权日:2019-09-16
标题:Treatment of disc degenerative disease and stimulation of proteoglycan synthesis by fibroblast conditioned media and formulations thereof